

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	EXECUTIVE ORDER 9424, CONFIRMATORY LICENSE
CONVEYING PARTY DATA	
Name	Execution Date
SCRIPPS RESEARCH INSTITUTE	12/15/1999
RECEIVING PARTY DATA	
Name:	National Institutes of Health (NIH), U.S. Dept. of Health and Human Services (DHHS), U.S. Government
Street Address:	NIH Division of Extramural Inventions and Technology Resources (DEITR)
Internal Address:	6705 Rockledge Drive, Suite 310, MSC 7980
City:	Bethesda
State/Country:	MARYLAND
Postal Code:	20892-7980
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	09194468
CORRESPONDENCE DATA	
Fax Number:	(301)480-0272
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Email:	edison@nih.gov
Correspondent Name:	Director, DEITR
Address Line 1:	NIH, 6705 Rockledge Drive, Suite 310
Address Line 2:	MSC 7980
Address Line 4:	Bethesda, MARYLAND 20892-7980
NAME OF SUBMITTER:	Director,DEITR, NIH
Total Attachments: 1 source=09194468mrs#page1.tif	

500682852

PATENT
REEL: 021720 FRAME: 0099

LICENSE TO THE UNITED STATES GOVERNMENT

This instrument confers to the United States Government, as represented by the Department of Health and Human Services, a nonexclusive, nontransferable, irrevocable, paid-up license to practice or have practiced on its behalf throughout the world the following subject invention:

TSRI No.: 419.2/93-084, 94-154

Invention Title: Methods and Compositions for Inhibition of Angiogenesis

Inventors: Peter Brooks and David Cheresh

Patent Application

Serial No.: 09/194,486⁶⁸

Filing Date: 3/23/99

Title: Methods and Compositions for Inhibition of Angiogenesis

**Country, if other
than United States:**

This subject invention was conceived or first actually reduced to practice in performance of a government-funded project, National Institutes of Health Grant No. CA 45726, CA50286 .

Principal rights to this subject invention have been left with the Licensor: **THE SCRIPPS RESEARCH INSTITUTE**, subject to the provisions of 37 CFR 401 and 45 CFR 8.

Signed: _____

Arnold LaGuardia
Senior Vice President
The Scripps Research Institute

Date: _____

12/15/99